[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasmacytoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasmacytoma":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100549064",false,"NCT06429150","Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma","Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy","Inclusion Criteria:\n\n* Male and female subjects with multiple myeloma or plasmacytoma\n* Strictly complete remission (sCR) is a treatment goal\n* Expected survival \\> 12 weeks\n* After prior auto-SCT is eligible regardless of other prior therapies\n* Adequate venous access for apheresis, and no other contraindications for leukapheresis\n* Voluntary informed consent is given and commitment to continued follow-up\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Uncontrolled active infection\n* Active HIV, hepatitis B or hepatitis C infection\n* Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.\n* Any medical conditions that may preclude participation","ALL","18 Years","80 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.",[27,28],"Multiple Myeloma","Plasmacytoma",[30,31,32,33],"multiple myeloma","chimeric antigen receptor","BCMA","GPRC5D","RECRUITING","2026-06-18",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":38},"2024-05-11",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"Shenzhen Geno-Immune Medical Institute","OTHER",""]